Identification of an antimalarial synthetic trioxolane drug development candidate

Nature

Volumn 430, Issue 7002, 2004, Pages 900-904

  Vennerstrom, Jonathan L ^a   Arbe Barnes, Sarah ^b   Brun, Reto ^c   Charman, Susan A ^d   Chiu, Francis C K ^d   Chollet, Jacques ^c   Dong, Yuxiang ^a   Dorn, Arnulf ^e   Hunziker, Daniel ^e   Matile, Hugues ^e   McIntosh, Kylie ^d   Padmanilayam, Maniyan ^a   Santo Tomas, Josefina ^c   Scheurer, Christian ^c   Scorneaux, Bernard ^c   Tang, Yuanqing ^a   Urwyler, Heinrich ^f   Wittlin, Sergio ^c   Charman, William H ^d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Fulcrum Pharma Developments Ltd   (United Kingdom)

^c SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^d MONASH UNIVERSITY   (Australia)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

^f BASILEA PHARMACEUTICA INTERNATIONAL LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATION; FREE RADICALS; PEROXIDES; PHARMACOKINETICS; PROTEINS; REDOX REACTIONS;

ANTIMALARIAL DRUGS; ARTEMISININ;

CHEMOTHERAPY;

1,2,4 TRIOXANE DERIVATIVE; ADENOSINE TRIPHOSPHATASE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISIN DERIVATIVE; ARTESUNATE; CHLOROQUINE; HEMOPROTEIN; MEFLOQUINE; TRIOXOLANE; UNCLASSIFIED DRUG;

MEDICINE;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG SYNTHESIS; ENDOPLASMIC RETICULUM; MALARIA; NONHUMAN; PARASITE SURVIVAL; PRIORITY JOURNAL; RAT; SARCOPLASMIC RETICULUM;

ANIMALS; ANTIMALARIALS; ARTEMISININS; BIOLOGICAL AVAILABILITY; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HALF-LIFE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; INHIBITORY CONCENTRATION 50; MALARIA; MICE; OXIDATION-REDUCTION; PEROXIDES; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; RATS; RATS, WISTAR; SESQUITERPENES; SOLUBILITY; SPIRO COMPOUNDS; TISSUE DISTRIBUTION;

ANIMALIA;

EID: 4344630762     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature02779     Document Type: Article

References (30)

1. Klayman, D. L. Qinghaosu (artemisinin): an antimalarial drug from China. Science 228, 1049-1055 (1985).
2. Jefford, C. W. Why artemisinin and certain synthetic peroxides are potent antimalarials. Implications for the mode of action. Curr. Med. Chem. 8, 1803-1826 (2001).
3. Cumming, J. N., Polypradith, P. & Posner, G. H. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Adv. Pharmacol. 37, 254-297 (1997).
4. Wu, Y. How might qinghaosu (artemisinin) and related compounds kill the intraerythrocytic malaria parasite? A chemist's view. Acc. Chem. Res. 35, 255-259 (2002).
5. Robert, A., Coppel, Y. & Meunier, B. Alkylation of heme by the antimalarial drug artemisinin. Chem. Commun., 414-415 (2002).
6. Meshnick, S. R. Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol. 32, 1655-1660 (2002).
7. Eckstein-Ludwig, U. et al. Artemisinins target the SERCA of Plasmodium falciparum Nature 424, 957-961 (2003).
8. White, N. J. Antimalarial drug resistance and combination chemotherapy. Phil. Trans. R. Soc. Lond. B 354, 739-749 (1999).
9. White, N. J. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob. Agents Chemother. 41, 1413-1422 (1997).
10. Avery, M. A., Chong, W. K. M. & Jennings-White, C. Stereoselective total synthesis of (+)-artemisinin, the antimalarial constituent of Artemisia annua L. J. Am. Chem. Soc. 114, 974-979 (1992).
11. Ridley, R. G. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415, 686-693 (2002).
12. Nwaka, S. & Ridley, R. G. Virtual drug discovery and development of neglected diseases through public-private partnerships. Nature Rev. Drug Discov. 2, 919-928 (2003).
13. Desjardins, R. E., Canfield, C. J., Haynes, J. D. & Chulay, J. D. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique, Antimicrob. Agents Chemother. 16, 710-718 (1979).
14. 2-bis-(7-chloroquinolin-4-yl)cyclohexane-1,2- diamine: Comparison of two stereoisomers and detailed evaluation of the S,S enantiomer, Ro 47-7737. Antimicrob. Agents Chemother. 41, 677-686 (1997).
15. 18O-Tracer studies of Fe(II)-induced decomposition of 1,2,4-trioxolanes (ozonides) derived from cyclopentenes and indenes. Inner-sphere electron transfer reduction of the peroxide linkage. J. Am. Chem. Soc. 121, 6556-6562 (1999).
16. van de Waterbeemd, H., Smith, D. A., Beaumont, K. & Walker, D. K. Property-based design: Optimisation of drug absorption and pharmacokinetics. J. Med. Chem. 44, 1313-1333 (2001).
17. Smith, D., Jones, B. C. & Walker, D. K. Design of drugs involving concepts and theories of drug metabolism and pharmacokinetics. Med. Res. Rev. 16, 243-266 (1996).
18. Palm, K., Stenberg, P., Luthman, K. & Artursson, P. Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14, 568-571 (1997).
19. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-26 (1997).
20. Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Mod. Chem. 45, 2615-2623 (2002).
21. Griesbaum, K., Liu, X., Kassiaris, A. & Scherer, M. Ozonolyses of O-alkylated ketoximes in the presence of carbonyl groups: a facile access to ozonides. Liebigs Ann./Recueil. 1381-1390 (1997).
22. Tang, Y., Dong, Y. & Vennerstrom, J. L. Synthetic peroxides as antimalarials. Med. Res. Rev. 24, 425-448 (2004).
23. Vennerstrom, J.L., Dong, Y., Chollet, J. & Matile, H. Spiro and dispiro 1,2,4-trioxolane antimalarials. US patent 6, 486, 199 (2002).
24. Vennerstrom, J.L. et al. Spiro and dispiro 1,2,4-trioxolane antimalarials. US continuation-in-part based on PCT/US02/19767 (filed 21 June 2002).
25. Chawira, A. N. & Warhurst, D. C. The effect of artemisinin combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro. J. Trop. Med. Hyg. 90, 1-8 (1987).
26. Li, A.-G. et al. The pharmacokinetics and bioavailability of dihydroartemisinin, arteether, artemether, artesunic acid and artelinic acid in rats. J. Pharm. Pharmacol. 50, 173-182 (1998).
27. Vyas, N., Avery, B. A., Avery, M. A. & Wyandt, C. M. Carrier-mediated partitioning of artemisinin into Plasmodium falciparum-infected erythrocytes. Antimicrob. Agents Chemother. 46, 105-109 (2002).
28. Gordi, T. & Lepist, E.-I. Artemisinin derivatives: Toxic for laboratory animals, safe for humans? Toxicol. Lett. 147, 99-107 (2004).
29. Keul, H. Über konstitution und entstehung der ozonide von bis-adamantyliden und von bis-bicyclo[3.3.1]non-9-yliden. Chem. Ber. 108, 1207-1217 (1975).
30. Crespi, C. L., Miller, V. P. & Penman, B. W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 248, 188-190 (1998).